Stock HYPE3 HYPERA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hypera S.A.

Equities

HYPE3

BRHYPEACNOR0

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 04:07:46 2024-04-26 pm EDT 		5-day change 1st Jan Change
28.55 BRL +5.16% Intraday chart for Hypera S.A. +0.71% -20.14%
Apr. 27 Hypera S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 Transcript : Hypera S.A., Q4 2023 Earnings Call, Mar 14, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,501 21,688 17,873 28,615 22,617 18,070 - -
Enterprise Value (EV) 1 21,657 22,481 22,947 35,360 29,998 25,833 24,612 24,461
P/E ratio 19.6 x 16.9 x 11.2 x 17 x 13.7 x 9.94 x 8.66 x 7.52 x
Yield 3% 3.42% 4.35% 2.72% 3.44% 4.4% 5.1% 6.83%
Capitalization / Revenue 6.83 x 5.3 x 3.01 x 3.79 x 2.86 x 2.09 x 1.89 x 1.74 x
EV / Revenue 6.57 x 5.5 x 3.86 x 4.69 x 3.79 x 2.99 x 2.57 x 2.35 x
EV / EBITDA 18 x 15.6 x 10.9 x 13.3 x 10.9 x 8.56 x 7.3 x 6.66 x
EV / FCF 46.9 x -30.2 x 50.6 x 66.8 x 19 x 14.6 x 11.1 x 9.78 x
FCF Yield 2.13% -3.31% 1.98% 1.5% 5.27% 6.84% 9.01% 10.2%
Price to Book 2.59 x 2.35 x 1.84 x 2.68 x 1.96 x 1.44 x 1.32 x 1.22 x
Nbr of stocks (in thousands) 630,453 633,218 632,219 633,064 632,654 632,909 - -
Reference price 2 35.69 34.25 28.27 45.20 35.75 28.55 28.55 28.55
Announcement Date 3/7/20 2/26/21 2/24/22 2/16/23 3/13/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,295 4,089 5,937 7,546 7,915 8,647 9,560 10,412
EBITDA 1 1,206 1,440 2,102 2,651 2,756 3,018 3,370 3,673
EBIT 1 1,086 1,319 1,968 2,483 2,518 2,696 3,083 3,377
Operating Margin 32.95% 32.26% 33.15% 32.9% 31.81% 31.18% 32.25% 32.43%
Earnings before Tax (EBT) 1 1,100 1,243 1,644 1,611 1,509 1,888 2,317 2,672
Net income 1 1,164 1,295 1,618 1,706 1,651 1,830 2,199 2,441
Net margin 35.33% 31.67% 27.25% 22.61% 20.86% 21.16% 23% 23.45%
EPS 2 1.819 2.029 2.530 2.657 2.606 2.873 3.297 3.796
Free Cash Flow 1 462.3 -744.2 453.3 529.3 1,581 1,766 2,218 2,502
FCF margin 14.03% -18.2% 7.63% 7.01% 19.98% 20.42% 23.21% 24.03%
FCF Conversion (EBITDA) 38.33% - 21.57% 19.97% 57.37% 58.51% 65.83% 68.11%
FCF Conversion (Net income) 39.71% - 28.02% 31.02% 95.77% 96.51% 100.89% 102.48%
Dividend per Share 2 1.070 1.170 1.230 1.230 1.230 1.255 1.457 1.950
Announcement Date 3/7/20 2/26/21 2/24/22 2/16/23 3/13/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q2
Net sales 1 1,626 1,494 1,896 2,036 2,121 1,698 2,231 2,138 1,847 1,827 2,262 2,331 2,201 -
EBITDA 1 566.9 505.7 683.3 727.2 735 587.5 790.7 797.2 580.7 647.8 779.2 843.4 725.7 -
EBIT 1 530.9 294.5 644 684 686.6 535.8 734.1 735.8 512 579.4 728.3 786.3 657.1 -
Operating Margin 32.64% 19.72% 33.98% 33.6% 32.37% 31.55% 32.9% 34.41% 27.72% 31.72% 32.2% 33.73% 29.85% -
Earnings before Tax (EBT) 1 - - - - 440.8 270 471.8 474.3 293.3 373.8 501.5 562.2 491.4 -
Net income 1 640.4 349.5 455.8 466 431.7 339.4 504.4 499.5 307.8 391.5 452.8 493.6 404.9 -
Net margin 39.37% 23.4% 24.04% 22.89% 20.35% 19.99% 22.61% 23.36% 16.67% 21.44% 20.02% 21.18% 18.4% -
EPS 2 0.5720 0.5500 0.7200 0.7300 0.6475 0.5400 0.7900 0.7822 0.4999 0.6200 0.7602 0.8250 0.6849 0.9600
Dividend per Share 2 0.3000 0.3100 0.3078 - - - - - 0.3063 - - - - -
Announcement Date 2/24/22 4/28/22 7/28/22 10/27/22 2/16/23 4/27/23 7/27/23 10/26/23 3/13/24 4/26/24 - - - -
1BRL in Million2BRL
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 794 5,074 6,745 7,381 7,763 6,543 6,392
Net Cash position 1 844 - - - - - - -
Leverage (Debt/EBITDA) - 0.551 x 2.414 x 2.544 x 2.678 x 2.573 x 1.942 x 1.74 x
Free Cash Flow 1 462 -744 453 529 1,581 1,766 2,218 2,502
ROE (net income / shareholders' equity) 13.7% 14.4% 17% 16.7% 14.9% 13.4% 15.4% 16.8%
ROA (Net income/ Total Assets) 10.4% 8.88% 8.73% 7.83% 6.84% 7.52% 8.35% 9.31%
Assets 1 11,238 14,585 18,534 21,787 24,132 24,335 26,339 26,216
Book Value Per Share 2 13.80 14.60 15.40 16.80 18.20 19.80 21.70 23.50
Cash Flow per Share 1.290 1.850 2.190 3.190 - - - -
Capex 1 362 1,927 946 1,509 815 1,069 1,084 936
Capex / Sales 10.98% 47.13% 15.93% 20% 10.29% 12.37% 11.34% 8.99%
Announcement Date 3/7/20 2/26/21 2/24/22 2/16/23 3/13/24 - - -
1BRL in Million2BRL
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hypera S.A.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
28.55 BRL
Average target price
41.12 BRL
Spread / Average Target
+44.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HYPERA S.A. Stock Hypera S.A.
-20.14% 3.53B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HYPE3 Stock
  4. Financials Hypera S.A.